Observational studyBMC endocrine disorders2026
COVID-19 infection prior to the onset of type 1 diabetes does not impair beta-cell function: a two-year nationwide follow-up study.
Observational study in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04623697 (Covid-19 and Type 1 Diabetes - a Multicenter Study), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Covid-19 and Type 1 Diabetes - a Multicenter Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA possible association between infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and type 1 diabetes (T1D) development has been reported. Whether SARS-CoV-2 infection affects beta-cell loss in T1D over time is unknown. We investigated this in adults with new-onset T1D.
methodsIndividuals with new T1D were included from six Danish hospitals between December 2020 and January 2023. Within one month after the diagnosis of T1D, we assessed medical history, previous self-reported COVID-19 infection, COVID-19 vaccination, glycated haemoglobin (HbA1c), and SARS-CoV-2 antibodies (Cov2IgG). A mixed-meal tolerance test (MMTT) was performed after overnight fast at baseline, and after 12 and 24 months to assess plasma glucose and C-peptide at 15-60 min intervals for up to 150 min. The main outcome was C-peptide area under curve (AUC
resultsA total of 94 individuals with T1D were included (34% were female) and 90 had available MMTT results. The mean age was 30.9 (SD 10.2) years, the mean HbA1c was 108 ± 25 mmol/mol (12.1 ± 2.29%), at enrolment. 17% were Cov2IgG positive at enrolment, indicating preceding COVID-19. The baseline median AUC
conclusionsAmong persons with new-onset T1D, 17% were Cov2IgG positive during the pandemic, which was higher than in the Danish background population. Assessed by MMTT, COVID-19 infection prior to T1D development did not affect insulin secretion or glycaemic control. CLINICAL TRIALS IDENTIFIER: NCT04623697 (registered on the 10th of November, 2020).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.